Moors & Cabot Inc. trimmed its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) by 42.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 12,750 shares of the company’s stock after selling 9,233 shares during the quarter. Moors & Cabot Inc.’s holdings in Elanco Animal Health were worth $128,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of the company. KB Financial Partners LLC boosted its position in Elanco Animal Health by 8.2% during the first quarter. KB Financial Partners LLC now owns 8,709 shares of the company’s stock worth $227,000 after purchasing an additional 658 shares in the last quarter. Baird Financial Group Inc. lifted its position in shares of Elanco Animal Health by 1.8% in the third quarter. Baird Financial Group Inc. now owns 47,406 shares of the company’s stock valued at $589,000 after acquiring an additional 843 shares in the last quarter. Captrust Financial Advisors lifted its position in shares of Elanco Animal Health by 57.0% in the first quarter. Captrust Financial Advisors now owns 2,690 shares of the company’s stock valued at $70,000 after acquiring an additional 977 shares in the last quarter. Resonant Capital Advisors LLC lifted its position in shares of Elanco Animal Health by 5.2% in the second quarter. Resonant Capital Advisors LLC now owns 20,784 shares of the company’s stock valued at $209,000 after acquiring an additional 1,028 shares in the last quarter. Finally, Nissay Asset Management Corp Japan ADV lifted its position in shares of Elanco Animal Health by 2.2% in the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 49,667 shares of the company’s stock valued at $607,000 after acquiring an additional 1,074 shares in the last quarter. 95.29% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
ELAN has been the topic of several recent research reports. Morgan Stanley reduced their price objective on Elanco Animal Health from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 8th. Piper Sandler upped their price objective on Elanco Animal Health from $11.00 to $12.00 and gave the company a “neutral” rating in a research report on Monday, November 13th. Stifel Nicolaus dropped their target price on Elanco Animal Health from $13.00 to $12.00 and set a “hold” rating for the company in a research note on Monday, October 30th. Finally, The Goldman Sachs Group upped their target price on Elanco Animal Health from $8.50 to $9.50 and gave the company a “sell” rating in a research note on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $12.70.
Elanco Animal Health Stock Performance
Elanco Animal Health stock opened at $11.88 on Tuesday. The firm has a market capitalization of $5.85 billion, a P/E ratio of -5.12, a PEG ratio of 7.03 and a beta of 1.02. The stock has a fifty day moving average price of $10.36 and a 200 day moving average price of $10.49. Elanco Animal Health Incorporated has a 52 week low of $7.88 and a 52 week high of $14.69. The company has a current ratio of 2.82, a quick ratio of 1.48 and a debt-to-equity ratio of 0.96.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last announced its quarterly earnings results on Tuesday, November 7th. The company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.12 by $0.06. The company had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.04 billion. Elanco Animal Health had a positive return on equity of 6.99% and a negative net margin of 26.18%. The firm’s revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.20 earnings per share. Equities research analysts anticipate that Elanco Animal Health Incorporated will post 0.92 earnings per share for the current year.
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
- Five stocks we like better than Elanco Animal Health
- Dividend Tax Calculator
- Safeguard your portfolio with these three bargain stocks
- Canadian Penny Stocks: Can They Make You Rich?
- Membership clubs gain leverage for the consumer rebound
- How to Invest in Energy
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.